Medimix Hematology
  • Home
  • Live from the congress
    • 2025
      • EBMT 2025
    • 2024
      • ASH 2024 (San Diego)
      • EHA 2024 (Madrid)
      • ASCO 2024 (Chicago)
  • Contact
  • Other specialties
    • Dermatology
    • Oncology
  • SIGN UP
  • SIGN IN
    • Login
ASH 2024

Longer survival with momelotinib than with best available therapy in ruxolitinib-pretreated myelofibrosis: results of a matching-adjusted indirect comparison

December 24, 2024

In a poster presented at the 2024 annual ASH meeting, Prof Francesca Palandri, haematologist in the IRCCS Azienda Ospedaliero at the University of Bologna (Italy), shared the results of a matching-adjusted, indirect comparison of momelotinib and best available therapy (BAT) in ruxolitinib-pretreated myelofibrosis patients. According to this analysis, momelotinib was associated with a longer overall survival (OS) than BAT, both in the overall study population and in the subgroup of patients with anemia at baseline. Together with the results of the SIMPLIFY-2 and MOMENTUM trials, these findings provide further support for the use of momelotinib as standard of care for myelofibrosis patients who discontinue their first line treatment with ruxolitinib.

According to Dr Heestermans, serial cfDNA analyses could improve the existing risk stratification of MM and inform clinicians about the emergence of (epi)genetic alterations with prognostic or therapeutic relevance. As such, this technique can contribute to a further personalization of the care for patients with MM.

Back to ASH 2024 overview

Made possible with the financial support of our partners.
All videos are developed independently and are non-promotional.

                                          

Tags:

poster

Share Article

Medimix Hematology

Website created by MediMix © 2025 - Privacy Policy

  • Home
  • Live from the congress
    • 2025
      • EBMT 2025
    • 2024
      • ASH 2024 (San Diego)
      • EHA 2024 (Madrid)
      • ASCO 2024 (Chicago)
  • Contact
  • Other specialties
    • Dermatology
    • Oncology
  • SIGN UP
  • SIGN IN
    • Login
    • Logout
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok